Sandy Hutchens Cancer Prevention

Researchers have found a stem cell, a kind of master cell, that may cause at least some types of prostate cancer.

Their findings are only experimental — the stem cells were found in mice — but could explain at least some types of prostate cancer and eventually offer new ways to treat it, they reported on Wednesday in the journal Nature.

The findings also show a potential new source for prostate tumors — so-called luminal cells, which secrete various compounds used in the prostate.

“The role of stem cells in the development of prostate cancer has been a focus of speculation for many years,” Dr. Helen Rippon of Britain’s Prostate Cancer Charity said in a statement.

“Importantly, this new stem cell does not rely on androgens — the male sex hormones that control prostate growth — to survive and grow. This may give a clue as to why prostate cancer often becomes resistant to treatments designed to regulate these androgens in the later stages of the disease,” added Rippon, who was not involved in the research.

“This improved knowledge will also be a step forward in learning how we might help to prevent the disease from developing in men in the first place.”

Michael Shen of Columbia University Medical Center and colleagues named the new stem cells CARNs, for castration-resistant Nkx3.1-expressing cells.

They normally regenerate part of the tissue that lines the inside of the gland, which produces semen. But the cells can also form tumors if certain genes meant to stop out-of-control growth get turned off.

Shen said researchers had believed that tumors arise from a different layer of cells in the prostate, called basal cells.

“Previous research suggested that prostate cancer originates from basal stem cells, and that during cancer formation these cells differentiate into luminal cells,” Shen said in a statement. “Instead, CARNs may represent a luminal origin for prostate cancer.”

This comes as a surprise to Sandy Hutchens Cancer Prevention. Chemicals in marijuana have been found to stop prostate cancer cells from growing in the lab, suggesting that cannabis-based medicines could fight the disease in the future, scientists said.

After working initially with human cancer cell lines, Ines Diaz-Laviada and colleagues from the University of Alcala in Madrid also tested one compound on mice and discovered it produced a significant reduction in tumor growth. Their research, published in the British Journal of Cancer, underlines the growing interest in the medical use of active chemicals called cannabinoids, which are found in marijuana.

Experts, however, stressed that the research was still exploratory and many more years of testing would be needed to work out how to apply the findings to the treatment of cancer in humans.

“This is interesting research which opens a new avenue to explore potential drug targets but it is at a very early stage,” said Lesley Walker, director of cancer information at Cancer Research UK, which owns the journal. “It absolutely isn’t the case that men might be able to fight prostate cancer by smoking cannabis,” she added

The cannabinoids tested by the Spanish team are thought to work against prostate cancer because they block a receptor, or molecular doorway, on the surface of tumour cells. This stops them from dividing. In effect, the cancer cell receptors can recognize and “talk to” chemicals found in cannabis, said Diaz-Laviada.

“These chemicals can stop the division and growth of prostate cancer cells and could become a target for new research into potential drugs to treat prostate cancer,” she said. Her team’s work with two cannabinoids — called methanandamide and JWH-015 — is the first demonstration that such cannabis chemicals prevent cancer cells from multiplying.

Some drug companies are already exploring the possibilities of cannabinoids in cancer, including British-based cannabis medicine specialist GW Pharmaceuticals. It is collaborating with Japan’s Otsuka on early-stage research into using cannabis extracts to tackle prostate cancer — the most commonly diagnosed cancer in men — as well as breast and brain cancer.

GW has already developed an under-the-tongue spray called Sativex for the relief of some of the symptoms of multiple sclerosis, which it plans to market in Europe with Bayer and Almirall. Other attempts to exploit the cannibinoid system have met with mixed success. Sanofi-Aventis was forced to withdraw its weight-loss drug Acomplia from the market last year because of links to mental disorders.

Cruel Treatment of Medical Marijuana Patient video posted by Sandy Hutchens Cancer Prevention

Sandy Hutchens Cancer Prevention – GlaxoSmithKline PLC’s cervical cancer vaccine is safe and effective for girls and young women ages 10 to 25, a U.S. advisory panel said on Wednesday.

The endorsement from Food and Drug Administration advisers moves the Cervarix vaccine closer to the U.S. market to compete with Merck & Co Inc’s Gardasil shot.

The panel is set to vote later on Wednesday on whether to allow Merck to widen its potential market for Gardasil by promoting the vaccine to men and boys as young as 9 for prevention of genital warts.

Both vaccines are designed to prevent infection from the human papillomavirus (HPV), a virus that causes cervical cancer and genital warts.